Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Innoviva, Inc. (NASDAQ: INVA).

Full DD Report for INVA

You must become a subscriber to view this report.


Recent News from (NASDAQ: INVA)

Research Report Identifies ILG, Innoviva, iRobot, KBR, KapStone Paper and Packaging, and Lumentum with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ILG Inc. (NASDAQ:ILG), Innoviva, Inc. (NASDAQ:INVA), iRobot Corporation (N...
Source: GlobeNewswire
Date: May, 08 2018 08:25
Blog Exposure - INSYS Commences Phase-2 Clinical Trial of Cannabidiol Oral Solution for Treatment of Prader-Willi Syndrome
Stock Monitor: Innoviva Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 01, 2018 / Active-Investors.com has just released a free research report on INSYS Therapeutics, Inc. (NASDAQ: INSY ) ("INSYS"). If you want access to this report all you need to do is sign up now by clickin...
Source: ACCESSWIRE IA
Date: May, 01 2018 07:50
Innoviva misses by $0.18, misses on revenue
Innoviva (NASDAQ: INVA ): Q1 EPS of $0.35 misses by $0.18 . More news on: Innoviva, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 26 2018 08:14
Innoviva Reports First Quarter 2018 Financial Results
Royalties earned rose 28% to $55.8 million compared with the first quarter of 2017. Net income attributable to Innoviva stockholders increased 76% from the first quarter of 2017 to $29.6 million, or $0.29 per basic share. Innoviva, Inc. (NASDAQ: INVA) (the Company) today reporte...
Source: Business Wire
Date: April, 26 2018 08:00
By The Numbers: Healthcare Stocks With Big Cash Distributions
The healthcare sector offers many attractive characteristics for investors. Health is a priority for most people around the world, so consumers are willing to pay considerable sums of money for drugs and treatments that can make a material difference in their quality of life. An aging populati...
Source: SeekingAlpha
Date: April, 24 2018 14:28
Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta c...
Source: Business Wire
Date: April, 24 2018 12:55
Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD
Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the publication in the ...
Source: Business Wire
Date: April, 18 2018 17:00
Adjusted Price Targets For This Bio-Pharmaceutical Holding Company: More Than 20% Upside
Context We had previously released an article stipulating that Innoviva (INVA) had 50% upside towards our “base” price target at $24.84 per share. However, we have since then updated the methods and techniques in our discounted cash flow valuation of the company. We have a...
Source: SeekingAlpha
Date: April, 17 2018 10:40
Innoviva Inc.: Buy This Small-Cap Biopharma Royalty Holding Company With 50% Upside
Business Overview Innoviva Inc. ( INVA ) is a small-cap biopharmaceutical royalty holding company that currently collects royalties on two marketed GlaxoSmithKline ( GSK ) respiratory products. The firm operates by providing up-front cash financing to firms with recently approved products ...
Source: SeekingAlpha
Date: April, 10 2018 09:25
By The Numbers: Profitable Stocks With Reasonable Valuations And Rising Earnings Expectations
Investing is always a matter of probabilities as opposed to certainties. There is no way to tell for certain how a specific asset or an investment strategy is going to perform in a particular period. On the other hand, statistical data shows that companies offering some specific quantitative a...
Source: SeekingAlpha
Date: March, 08 2018 08:12

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1814.6714.6614.8114.63384,476
2018-05-1714.6714.6614.8114.63384,476
2018-02-2616.1015.9316.3215.865628,876
2018-02-2316.2016.1016.2015.815444,708
2018-02-2216.4016.2116.5216.07525,587

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1492,572132,22370.0120Short
2018-08-1327,67949,57955.8281Short
2018-08-1097,281143,01868.0201Short
2018-08-0959,49688,74567.0415Short
2018-08-0853,600111,88547.9063Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INVA.


About Innoviva, Inc. (NASDAQ: INVA)

Logo for Innoviva, Inc. (NASDAQ: INVA)

Not available

 

Contact Information

 

 

Current Management

  • Rick E. Winningham / CEO
  • Marty Glick / CFO

Current Share Structure

  • Market Cap: $1,652,609,282 - 03/21/2018
  • Issue and Outstanding: 101,824,355 - 02/16/2018

 


Recent Filings from (NASDAQ: INVA)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 10 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 10 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 10 2018

 

 


Daily Technical Chart for (NASDAQ: INVA)

Daily Technical Chart for (NASDAQ: INVA)


Stay tuned for daily updates and more on (NASDAQ: INVA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: INVA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INVA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of INVA and does not buy, sell, or trade any shares of INVA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/